THERAPEUTICS
Benefits of early intensive glucose control to prevent diabetes complications were sustained for up to 10 years
| The first 150 words of the full text of this article appear below. |
R R Holman
Dr R R Holman, Diabetic Trials Unit, Oxford, UK; rury.holman@dtu.ox.ac.uk
STUDY DESIGN
randomised controlled trial (UK Prospective Diabetes Study [UKPDS]). Current Controlled Trials ISRCTN75451837 [controlled-trials.com] .
{concealed}*.
blinded (outcome adjudication committee).
STUDY QUESTION
23 centres in the UK.
4209 patients 25–65 years of age {mean age 53 y, 60% men}* who had newly diagnosed type 2 diabetes and fasting plasma glucose concentrations >6.0 mmol/l (108 mg/dl) and <15.0 mmol/l (270 mg/dl) after 3 months of dietary therapy. Exclusion criteria included recent myocardial infarction, current angina or heart failure, and >1 major vascular event.
intensive glucose control with a sulfonylurea or insulin (n = 2729) or conventional therapy with diet (n = 1138). Overweight patients were also allocated to a third group involving intensive therapy with metformin (n = 342).
7 composite outcomes (any diabetes-related end point, diabetes-related death, death from any cause, myocardial infarction, stroke, peripheral vascular disease, and microvascular disease).
median
University Hospital, Galway, Ireland
National University of Ireland, Galway, Ireland
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
